A5058727428- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- Lymphoma Diagnosis and Treatment
- Advanced Breast Cancer Therapies
- Immunodeficiency and Autoimmune Disorders
- Phagocytosis and Immune Regulation
- Monoclonal and Polyclonal Antibodies Research
- Chronic Myeloid Leukemia Treatments
- Tea Polyphenols and Effects
- Autoimmune Neurological Disorders and Treatments
- Cellular transport and secretion
- Viral-associated cancers and disorders
- PI3K/AKT/mTOR signaling in cancer
- Synthesis and biological activity
- CAR-T cell therapy research
- Viral gastroenteritis research and epidemiology
- Enzyme function and inhibition
- Histone Deacetylase Inhibitors Research
- Immune Cell Function and Interaction
- Renal Diseases and Glomerulopathies
- Respiratory viral infections research
- Calcium signaling and nucleotide metabolism
- Platelet Disorders and Treatments
- Multiple Myeloma Research and Treatments
- Immune Response and Inflammation
WinnMed
2022-2025
Mayo Clinic
2007-2024
Mayo Clinic in Arizona
2014-2024
Khon Kaen University
2023
United States Nuclear Regulatory Commission
2023
University of Virginia
2023
Euroimmun Medizinische Labordiagnostika (Germany)
2023
Mayo Clinic in Florida
2018-2020
University of Guelph
1988-1990
Abstract BACKGROUND: The objective of the current study was to follow up results phase 1 testing by evaluating clinical efficacy green tea extract Polyphenon E for patients with early stage chronic lymphocytic leukemia (CLL). METHODS: Previously untreated asymptomatic, Rai 0 II CLL and an absolute lymphocyte count (ALC) ≥ 10 × 9 /L were eligible this 2 trial. a standardized dose epigallocatechin gallate (EGCG) (2000 mg per dose) administered twice daily. RESULTS: A total 42 received at 2000...
B-cell chronic lymphocytic leukemia (CLL) is an incurable disease despite aggressive therapeutic approaches. We previously found that Axl receptor tyrosine kinase (RTK) plays a critical role in CLL survival. Here, we explored the possibility of using high-affinity inhibitor as single agent or combination with Bruton's (BTK) inhibitors for future clinical trial to treat patients CLL.Expression/activation status other members TAM (e.g., Tyro3, Axl, and MER) family RTKs B cells was evaluated....
Monoclonal B-cell lymphocytosis (MBL) is a common hematological premalignant condition that understudied in screening cohorts. MBL can be classified into low-count (LC) and high-count (HC) types based on the size of clone. Using Mayo Clinic Biobank, we screened for evaluated its association with future hematologic malignancy overall survival (OS). We had two-stage study design including discovery validation using an eight-color flow-cytometry assay. Medical records were abstracted cancers...
<h3>Background and Objectives</h3> Neural antibodies are detected by tissue-based indirect immunofluorescence assay (IFA) in Mayo Clinic9s Neuroimmunology Laboratory practice, but the process of characterizing validating novel is lengthy. We report our assessment human protein arrays. <h3>Methods</h3> Assessment arrays (81% proteome coverage) was undertaken using diverse known positive samples (17 serum 14 CSF). Samples from patients with neural were reflexed IFA to Confirmatory assays...
Bruton tyrosine kinase inhibitors (BTKis) that target B-cell receptor signaling have led to a paradigm shift in chronic lymphocytic leukemia (CLL) treatment. BTKis been shown reduce abnormally high CLL-associated T-cell counts and the expression of immune checkpoint receptors concomitantly with tumor reduction. However, impact BTKi therapy on function has not fully characterized. Here, we performed longitudinal immunophenotypic functional analysis pretreatment on-treatment (6 12 months)...
Objectives To report an autoimmune paraneoplastic encephalitis characterized by immunoglobulin G (IgG) antibody targeting synaptic protein calmodulin kinase‐like vesicle‐associated (CAMKV). Methods Serum and cerebrospinal fluid (CSF) samples harboring unclassified antibodies on murine brain‐based indirect immunofluorescence assay (IFA) were screened human microarray. In 5 patients with identical cerebral IFA staining, CAMKV was identified as top‐ranking candidate antigen. Western blots,...
Activation of acid sphingomyelinase (ASM) leads to ceramide accumulation and induces apoptotic cell death in cancer cells. In the present study, we demonstrate that activation ASM by targeting cancer-overexpressed 67-kDa laminin receptors (67LR) lipid raft disruption inhibits receptor tyrosine kinase (RTK) multiple myeloma Sphingosine 1 (SphK1), a negative regulator with antiapoptotic effects, was markedly elevated The silencing SphK1 potentiated effects green tea polyphenol...
Most human cancers converge to a deregulated methylome with reduced global levels and elevated methylation at select CpG islands. To investigate the emergence dynamics of cancer methylome, we characterized genome-wide DNA in pre-neoplastic monoclonal B cell lymphocytosis (MBL) chronic lymphocytic leukemia (CLL), including serial samples collected across disease course. We detected aberrant tumor-associated landscape CLL diagnosis found no significantly differentially methylated regions...
Akt is a downstream target of B cell receptor signaling and central regulator CLL survival. We aim to investigate the safety efficacy inhibitor MK‐2206 in combination with bendamustine rituximab (BR) relapsed and/or refractory phase I/II study. A standard I design was used cohorts three plus patients determine maximum tolerated dose (MTD) BR CLL. Single‐agent (weekly dosed) administered one‐week advance before on cycle 1 subsequently given at same time for 2‐6. Phase II employed MTD evaluate...
Abstract Monoclonal B-cell lymphocytosis (MBL) is a precursor to CLL. Other than age, sex, and CLL family-history, little known about factors associated with MBL risk. A polygenic-risk-score (PRS) of 41 CLL-susceptibility variants has been found be risk among individuals European-ancestry(EA). Here, we evaluate these variants, the PRS, environmental for We also CLL-PRS African-American (AA) EA-CLL cases controls. Our study included 560 EA MBLs, 869 CLLs (696 EA/173 AA), 2866 controls (2631...
// Neil E. Kay 1 , Paolo Strati Betsy R. LaPlant Jose F. Leis 2 Daniel Nikcevich 3 Timothy G. Call Adam M. Pettinger Connie Lesnick Curtis A. Hanson and Tait D. Shanafelt Mayo Clinic College of Medicine, Rochester, MN, USA Scottsdale, AZ, Essentia Health's East Region, Duluth, Correspondence to: Kay, email: Keywords : CLL, chemoimmunotherapy, bevacizumab Received October 15, 2016 Accepted November 09, Published 16, Abstract Bevacizumab is a monoclonal antibody targeting vascular endothelial...
e20009 Background: Although treating B-Chronic Lymphocytic Leukemia (CLL) with small molecule inhibitors has shown promise, a lasting cure for this disease yet to be found. Further treatments directed at key molecular targets in the CLL B cell need development patients adverse prognostic factors, and relapsed/refractory patients. We evaluated impact of two novel drugs non-overlapping mechanisms action on cells: Voruciclib, cyclin dependent kinase (CDK) inhibitor targeting CDKs 9, 6, 4, 1...